RxDoctor Payments Data

Mehjabeen Mujtaba, NP

Family · Paterson, NJNPI 1497432587

Payments from drug & device makers

$2,731in general payments, 2019–2025

Across 38 payments — averaging $71.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$666
  • Exact Sciences$439
  • Amgen$391
  • Madrigal Pharmaceuticals$293
  • Abbott$158
  • Bayer$150
  • plus $634 from 8 others

What the payments were for

  • Food & beverage$2,731100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,731 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,146
Medicare patients
13
Services billed
16

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate65$60,381
JanumetSitagliptin Phos/Metformin Hcl59$45,026
FarxigaDapagliflozin Propanediol52$42,513
JardianceEmpagliflozin37$30,050
OzempicSemaglutide23$25,440
TradjentaLinagliptin32$19,093
TrulicityDulaglutide11$14,216
LinzessLinaclotide13$12,174
EliquisApixaban11$8,450
VascepaIcosapent Ethyl18$6,870
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$6,255
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$5,161
Albuterol Sulfate HfaAlbuterol Sulfate204$4,415
Omega-3 Acid Ethyl Esters26$4,402
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$4,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$666$42,51352 claims
Lilly USA, LLCTrulicity$52$14,21611 claims
AbbVieLinzess$18$12,17413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.

Other family in Paterson

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →